Navigation Links
Even Tiny Breast Tumors May Need Aggressive Treatment
Date:12/17/2007

For a subset of cancer types, treatment needs to be much tougher than is typically done, study finds

MONDAY, Dec. 17 (HealthDay News) -- Even if they're very small (1 centimeter or less), certain kinds of breast cancer tumors can still be aggressive and require maximum therapy, U.S. researchers say.

A team at the Mayo Clinic in Jacksonville, Fla., found that outcomes for women with HER2 positive (HER2+) and triple negative (HER2- and ER/PR-) tumors that have not spread to the lymph nodes may not depend on tumor size alone.

About 15 percent to 20 percent of breast cancers are HER2+, and about 10 percent to 15 percent are triple negative.

"This is a small study, and so we can't make treatment recommendations from it, but it appears that biology and not only size matters when it comes to selecting therapy for small, invasive tumors," lead researcher Dr. Surabhi Amar, a fellow in hematology/oncology, said in a prepared statement.

Amar noted there are no definitive treatment guidelines for breast cancer tumors less than one centimeter in size, because most studies include women with larger tumors or with breast cancer that's spread to the lymph nodes.

"We just don't have extensive data on tumors this small, so treatment becomes a matter of physician discretion," Amar said.

The study included 401 breast cancer patients: 350 with HER2 negative/ER/PR+ tumors; 27 with HER2+ tumors; and 24 with triple negative tumors. The women were followed for an average of about three years.

The researchers found that women with HER2+ and triple negative cancers were more likely (92 percent and 91 percent, respectively) to have grade 2 and 3 tumors than women with HER2 negative/ER/PR+ cancer (36 percent). Tumors are graded from 1 to 3. Higher grade tumors are more likely to grow faster and be difficult to treat.

The study also found that cancer recurrence was more common in women with HER2+ tumors (7.4 percent) and triple negative tumors (12.5 percent) than in women with HER2 negative/ER/PR+ tumors (1.3 percent).

The overall outcome for all the women with these small, lymph-node-negative tumors was excellent -- overall survival was 97.4 percent and disease-free survival 95.1 percent. One of the 24 patients with triple negative cancer died, none of the 24 women with HER2+ died, and one of the 219 women with HER2 negative/ER/PR+ cancer died.

The study findings suggest that women with small HER2+ and triple negative breast tumors should receive as much treatment as possible in order to prevent cancer relapse, Amar said.

But that doesn't appear to be happening. The study found that only 35 percent of women with triple negative cancers and 28 percent of those with HER2+ tumors received adjuvant chemotherapy (chemotherapy after surgery).

The study was to be presented Dec. 16 at the San Antonio Breast Cancer Symposium.

More information

The American Cancer Society has more about breast cancer.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Dec. 16, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
Breaking Medicine Technology: